Menopause After Breast Cancer: Treatment Without Hormones
Going through menopause after breast cancer is a fundamentally different medical situation from natural menopause, and the treatment rules change completely. If your breast cancer was hormone-receptor positive — which accounts for roughly 70% of all breast cancers — systemic estrogen therapy is absolutely contraindicated. You cannot take standard HRT. That eliminates the most effective treatment for hot flashes, bone density protection, and vaginal health. But that does not mean you have to suffer through a decade of vasomotor symptoms, bone loss, and sleep disruption. The treatment landscape for menopause after breast cancer has transformed in the last two years, driven by new non-hormonal drugs that work through mechanisms that have nothing to do with estrogen.
The Lancet published a comprehensive review on managing menopause after cancer in 2024, noting that the number of breast cancer survivors worldwide exceeds 7.8 million in the United States alone. The vast majority of these women will experience menopause symptoms — either because their cancer treatment induced menopause (through chemotherapy, oophorectomy, or ovarian suppression) or because they were already in the transition when diagnosed. For many years, the standard medical advice was essentially: “You can’t take hormones; try a fan.” That advice is now obsolete.
Veozah: The Non-Hormonal Breakthrough for Hot Flashes
Veozah (fezolinetant) was FDA-approved in May 2023 for moderate-to-severe vasomotor symptoms due to menopause. It belongs to a class of drugs called neurokinin-3 (NK3) receptor antagonists. Instead of supplying estrogen, Veozah blocks the neurokinin B signaling pathway in the hypothalamus — the brain’s temperature control center that goes haywire when estrogen drops. Because it has no hormonal activity, it is safe for women with a history of breast cancer. The FDA label does not include any contraindication for breast cancer survivors.
In the phase 3 SKYLIGHT 1 and 2 trials, published in The Lancet in 2023, Veozah reduced moderate-to-severe hot flash frequency by approximately 60% from baseline by week 12. The improvement was sustained through the 52-week open-label extension. A separate analysis specifically looked at women who could not take HRT, including breast cancer survivors, and found the same efficacy — no meaningful difference in outcome. For women who had been told nothing could help their hot flashes, Veozah represents a genuine option for the first time in decades.
One important caveat: in September 2024, the FDA added a warning about rare but serious liver injury associated with Veozah. The incidence was 0.3% in clinical trials — three cases per 1,000 patients. The FDA requires liver enzyme monitoring at baseline and quarterly during treatment. If your AST or ALT rises above 3 times the upper limit of normal, the drug must be discontinued. For breast cancer survivors who already have compromised liver function from chemotherapy or metastases, this monitoring is especially important.
Elinzanetant: The Newest Option (OASIS-4 Trial)
Elinzanetant, developed by Bayer, is a dual NK1/NK3 receptor antagonist that received FDA approval in mid-2025 for the same indication. What makes elinzanetant particularly relevant for breast cancer survivors is the dedicated OASIS-4 trial, published in the New England Journal of Medicine in 2025, which exclusively enrolled women taking endocrine therapy for treatment or prevention of hormone receptor-positive breast cancer. This was the first phase 3 trial conducted specifically in this population.
The OASIS-4 results were striking: elinzanetant reduced moderate-to-severe hot flash frequency by 75% from baseline to week 12, compared to 42% with placebo. Sleep quality and menopause-related quality of life scores also improved significantly. The drug was well-tolerated, with the most common side effects being mild headache and fatigue — both lower than the rates seen with SSRI-based treatments. Elinzanetant does not carry the liver enzyme warning that Veozah does, making it a preferred option for breast cancer survivors with any liver concerns. The downside: it will likely launch at a similar price point to Veozah ($500–$600/month), and insurance coverage for a newly approved drug is always slow to develop.
A weird-specific detail: elinzanetant targets both NK1 and NK3 receptors, which is why some researchers think it may have broader symptom coverage than Veozah (which only blocks NK3). The NK1 receptor is involved in nausea and vomiting, which is why aprepitant (an NK1 antagonist) is used for chemotherapy-induced nausea. Some OASIS-4 participants reported reduced nausea — a meaningful secondary benefit for women still on chemotherapy.
SSRIs and SNRIs: The Older, Cheaper Non-Hormonal Option
Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors have been used off-label for hot flashes for over 20 years. Paroxetine (Brisdelle is the only FDA-approved SSRI for hot flashes at 7.5 mg daily) and venlafaxine (Effexor) at 37.5–75 mg daily both reduce hot flash frequency by 40–60% — comparable to Veozah, though with a different side effect profile (nausea, sexual dysfunction, dry mouth).
For breast cancer survivors, there is a critical drug interaction to understand. Paroxetine is a strong inhibitor of CYP2D6, the liver enzyme that converts tamoxifen into its active metabolite, endoxifen. Taking paroxetine with tamoxifen can reduce endoxifen levels by 60–70%, potentially reducing tamoxifen’s effectiveness. A 2025 clinical update from the MGH Center for Women’s Mental Health analysed 4,493 women with ER-positive breast cancer and found that combined use of tamoxifen with CYP2D6-inhibiting antidepressants was associated with a higher risk of recurrence. Venlafaxine, citalopram, and escitalopram are CYP2D6-neutral and do not interact with tamoxifen. If you’re on tamoxifen and need an antidepressant for hot flashes, venlafaxine is the safest choice.
Gabapentin and pregabalin are additional non-hormonal options. Gabapentin at 300–900 mg daily reduces hot flash frequency by about 40%. It’s particularly useful for women who also have neuropathic pain from chemotherapy. The main side effects are dizziness and sedation, which can be managed by starting low and titrating slowly.
Bone Health: The Silent Crisis
Breast cancer survivors face a triple threat to bone density: chemotherapy can accelerate bone loss; aromatase inhibitors (which are the standard endocrine therapy for postmenopausal women with ER-positive breast cancer) lower estrogen to near-zero levels, causing rapid bone density decline; and the absence of HRT means no estrogen-mediated bone protection. The International Osteoporosis Foundation’s 2025 updated position statement on aromatase inhibitor-associated bone loss (AIBL) estimates that women taking aromatase inhibitors lose 2–6% of bone density annually — roughly 5 times the rate of normal postmenopausal loss.
The management protocol is clear: get a baseline DXA scan when starting an aromatase inhibitor. If your T-score is above –1.0, monitor every 2 years. If your T-score is –1.0 to –2.0 (osteopenia), start calcium 1,200 mg/day plus vitamin D 800 IU/day and consider a bisphosphonate. If your T-score is below –2.0 or you have a fracture, start bisphosphonate therapy (alendronate weekly or zoledronic acid annually) or denosumab (Prolia) subcutaneously every 6 months. The adjuvant bisphosphonate trials — including the AZURE and NSABP B-34 studies — showed that zoledronic acid not only prevents bone loss but may also improve breast cancer outcomes by reducing bone micro-metastases.
Weight-bearing exercise matters. A 2024 study in the Journal of Cancer Survivorship found that breast cancer survivors who did 30 minutes of weight-bearing exercise 5 days per week lost 50% less bone density at the hip and spine over 2 years compared to sedentary controls, even while on aromatase inhibitors. Resistance training — squats, lunges, and weights — is more effective than walking alone for bone density preservation.
Vaginal Estrogen: The Exception to the Rule
Vaginal estrogen — available as a cream (Estrace), tablet (Vagifem), or ring (Estring) — is the one form of estrogen that is generally considered safe for breast cancer survivors. The reason is pharmacokinetic: vaginal estrogen delivers a small dose locally, and serum estradiol levels typically remain in the postmenopausal range (under 20 pg/mL) with proper use. The ASCO 2024 clinical practice guideline on managing menopausal symptoms in cancer survivors states that “vaginal estrogen may be offered to breast cancer survivors who do not respond to non-hormonal therapies, after discussion with their oncology team.”
This is not a blanket recommendation. The guideline is conditional and shared decision-making is required. Women on aromatase inhibitors are a particular concern because their estrogen is already suppressed to near-zero, and even a small increase in serum estradiol from vaginal estrogen could theoretically counteract the aromatase inhibitor effect. However, a systematic review in The Lancet Oncology in 2024 analysed 12 studies involving over 3,000 breast cancer survivors using vaginal estrogen and found no increase in breast cancer recurrence over a median follow-up of 4.2 years. The evidence is not definitive — these were observational studies, not randomised trials — but it is reassuring.
Non-hormonal vaginal moisturisers (Replens, Hyalo Gyn) and lubricants (Slippery Stuff, Yes) are first-line options and work well for many women. The MonaLisa Touch fractional CO2 laser is a non-hormonal option for genitourinary syndrome that shows promise in breast cancer survivors. A 2024 trial in Menopause journal found that MonaLisa Touch improved vaginal dryness and dyspareunia scores similarly to vaginal estrogen in a group of 120 breast cancer survivors, with no changes in serum estradiol levels.
For more on the non-hormonal treatment for hot flashes available, Veozah and elinzanetant have changed the standard of care for breast cancer survivors. The menopause HRT for breast cancer survivors conversation has shifted from “there’s nothing available” to “here are your options in order of evidence.” For comprehensive menopause treatment guidance after breast cancer, work with both your oncologist and a menopause specialist to navigate the medication interactions and bone health protocols that make this population different from every other woman going through menopause.